At a glance
- Originator Aventis
- Class Neuroprotectants; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 07 Jan 2000 Discontinued-Preclinical for Neurological disorders (Prevention) in France (Unknown route)
- 23 Dec 1999 Rhône-Poulenc Rorer has merged with Hoechst Marion Roussel to form Aventis Pharma
- 31 Jan 1995 Preclinical development for Neurological disorders (Prevention) in France (Unknown route)